The case of eculizumab: litigation and purchases by the Brazilian Ministry of Health.
Rosangela CaetanoPaulo Henrique de Almeida RodriguesMarilena Cordeiro Dias Villela CorrêaPedro VillardiClaudia Garcia Serpa Osorio-de-CastroPublished in: Revista de saude publica (2020)
Eculizumab represented extremely significant expenditures for the Brazilian Ministry of Health during the period. All purchases were made to meet demands from lawsuits, outside the competitive environment. The market approval of eculizumab promoted an important price reduction. This study indicates the relevance of licensing and the need for permanent monitoring and auditing of drug purchases to meet legal demands.